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ABSTRACT
Purpose: Telotristat ethyl, an oral tryptophan hy-
droxylase inhibitor, is intended to treat carcinoid syn-
drome by reducing serotonin production. Telotristat
ethyl was evaluated in TELESTAR, a Phase III study
for patients who had carcinoid syndrome with at least 4
bowel movements (BMs) per day and who were receiv-
ing somatostatin analogue therapy. This interview sub-
study was conducted to provide insight into the patient
experience in TELESTAR and to help understand
whether reductions in BM frequency (the primary end
point) and other symptoms were clinically meaningful.
Methods: Participating sites were asked to invite
(before randomization) all eligible patients to telephone
interviews scheduled at the end of the double-blind
treatment period. Patients and interviewers were
blinded to treatment.
Findings: All 35 interviewed participants reported
diarrhea and/or excessive BMs at baseline. Patients
reported that these symptoms negatively affected emo-
tional, social, physical, and occupational well-being.
Prespecified criteria for treatment response (achieving
≥30% reduction in BM frequency for at least 50% of
the days) were met by 8 of 26 patients taking telotristat
ethyl and 1 of 9 patients taking placebo. All 8 patients
taking telotristat ethyl described clinically meaningful
reductions in BM frequency and were very satisfied with
the ability of the study drug to control their carcinoid
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syndrome symptoms. Overall, reports of being very
satisfied were observed in 12 patients taking telotristat
ethyl and 0 taking placebo.
Implications: Patient interviews revealed that
TELESTAR patients, at baseline, were significantly
affected by their high BM frequency. Patient reports of
their clinical trial experience supported the signifi-
cance of the primary end point and clinical responder
analysis in TELESTAR, helping identify and under-
stand clinically meaningful change produced by telo-
tristat ethyl. (Clin Ther. 2017;39:2158–2168) & 2017
The Authors. Published by Elsevier HS Journals, Inc.
Key words: bowel movement, carcinoid syndrome,
diarrhea, exit interviews, patient interviews, telotristat
ethyl.
INTRODUCTION
Well-differentiated neuroendocrine tumor (NET), for-
merly known as carcinoid tumor, is a relatively rare
tumor type that arises from cells of the diffuse neuro-
endocrine cell system.1,2 Carcinoid syndrome occurs
when well-differentiated NET secretes large amounts
of serotonin and other vasoactive products into the
systemic circulation. Classically, symptoms associated
with carcinoid syndrome include cutaneous flushing,
diarrhea, wheezing, abdominal pain, and valvular
heart disease.3 The prevalence of well-differentiated
NET is approximately 50,000 cases in any 1 year in
the United States, as reported by Vinik et al.4
A detailed analysis based on Surveillance,
Epidemiology, and End Results data5 estimates the
2004 prevalence of NET to be 103,312 cases.2 Well-
differentiated NETs represent approximately half of
all NETs.6 However, not all well-differentiated
NETs will result in carcinoid syndrome. It has
been estimated that 10% of all patients with well-
differentiated NETs will develop carcinoid syndrome.7
Approximately 75% of patients with carcinoid
syndrome will experience diarrhea.8,9
The most common symptoms of carcinoid syn-
drome include diarrhea, paroxysmal facial flushing,
difficulty breathing, rapid heartbeat, and right-sided
heart disease or failure.10–13 These symptoms are the
result of biochemical secretions (most prominently
serotonin for diarrhea) from carcinoid tumors into
the bloodstream.10 Patients with carcinoid syndrome
have various combinations of these symptoms. Several
studies14,15 have found that patients experiencing 2 of
the most common symptoms of carcinoid syndrome,
flushing and diarrhea, have significantly impaired quality
of life. Among patients with carcinoid syndrome who
report increased frequency of bowel movements (BMs),
health-related quality-of-life impairments are worst in
those reporting ≥4 BMs per day.14
In addition to treatment of the underlying tumor
disease, patients with carcinoid syndrome typically
receive medications to control specific symptoms,
including injections of somatostatin analogues, such
as octreotide or lanreotide, to help control diarrhea
along with conventional antidiarrheal therapy.10,16
Telotristat ethyl, an oral tryptophan hydroxylase
inhibitor, may improve carcinoid syndrome symptoms
by reducing serotonin production by NET cells.
Telotristat ethyl was evaluated in TELESTAR, a phase
III placebo-controlled study for patients with carci-
noid syndrome diarrhea, who were receiving soma-
tostatin analogue therapy and who had uncontrolled
BMs (mean, ≥4 per day). One hundred thirty-five
participants were randomized 1:1:1 to receive placebo
TID or telotristat ethyl (250 or 500 mg) TID. The
primary end point of the TELESTAR study was the
change from baseline in the number of daily BMs
averaged during a 12-week, double-blind treatment
period. TELESTAR methods and the pivotal study
results have been described previously.17
Briefly, estimated differences from baseline in BM
frequency versus placebo averaged during 12 weeks
were –0.81 and –0.69 BMs per day for telotristat ethyl
250 mg (P o 0.001) and 500 mg (P o 0.001),
respectively. At week 12, mean BM frequency reduc-
tions for placebo, telotristat ethyl 250 mg, and
telotristat ethyl 500 mg were –0.9, –1.7, and –2.1
BMs per day, respectively. Durable responses, prede-
fined as BM frequency reductions of ≥30% from
baseline for ≥50% of the double-blind treatment
period, occurred in 20%, 44%, and 42% of patients
given placebo, telotristat ethyl 250 mg, and telotristat
ethyl 500 mg, respectively. The overall incidences of
adverse events and treatment discontinuation were
similar between the groups.
The European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire
(QLQ-C30), which was assessed among all random-
ized patients in the study, has the value of being
assessed systematically in all patients and being
supported by prior scientific literature, whereas the
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exit interviews provide a more individualized and
qualitative understanding that directly connects
patient symptoms and experiences. Qualitative inter-
views conducted with patients exiting a phase II
clinical trial of telotristat ethyl signaled the importance
and effect of BM frequency18; however, a more robust
understanding of the patient experience with carcinoid
syndrome (both before and during treatment) was
desired for TELESTAR. Therefore, the aim of the
present study was to explore patients’ experiences
with carcinoid syndrome and the extent to which, if at
all, treatment affected their experiences by conducting
prospective, qualitative exit interviews with volunteers
from TELESTAR. Specific objectives of the interview
study included (1) gaining a comprehensive
understanding of patients’ experiences with carcinoid
syndrome before the start of the TELESTAR study; (2)
identifying, from the patient perspective, which
symptoms were most important to treat and most
bothersome; (3) assessing patients’ perspectives on the
treatment benefit of blinded study drug; (4) gathering
further insight into the relevance and clinical
meaningfulness of specific symptom improvements
(such as reduction in BM frequency); and (5)
assessing patient satisfaction with telotristat ethyl.
The conduct of this qualitative exit interview study
was identified as the optimal method to assess the full
effect of symptoms, the relative importance of
symptoms, and the meaningfulness of symptom
improvement directly from patients.
METHODS
Clinical sites in 5 countries (Australia, Canada, Eng-
land, Germany, and the United States) invited partic-
ipants in the TELESTAR clinical study to take part in
an exit interview after their end-of-treatment visit at
week 12. These 5 countries (of 12) were selected to
maximize enrollment while limiting the number of
languages required. All interview procedures were
prespecified in the TELESTAR protocol and were
approved by ethics committees; all participants in
the exit interview study provided written informed
consent. Interviews were conducted by telephone in
English or German approximately 2 weeks after a
patient’s end-of-treatment visit by senior researchers
in the Patient-Reported Outcomes Division at RTI
Health Solutions (Research Triangle Park, North
Carolina), a pharmaceutical/biotech consulting research
organization. Patients, clinical sites, and interviewers
were blinded to treatment group assignment. All
interviews were audio recorded and transcribed.
Each interview was conducted using a semistruc-
tured interview guide and was divided into 2 phases.
Phase I of the interview focused on the patient’s
carcinoid syndrome symptom experiences before the
study. Patients were asked open-ended questions to
identify (and define in their own words) a compre-
hensive list of their carcinoid syndrome symptoms.
Once an exhaustive list of symptoms associated with
carcinoid syndrome was elicited, ranking methods
were used to narrow the full list of carcinoid syn-
drome symptoms to include only those of greatest
importance to each patient. Specifically, patients were
asked to report the 3 symptoms they most wanted to
see improve with treatment and then to rank these
symptoms in order of importance. Patients were then
queried about the daily effect of their carcinoid
syndrome symptoms (eg, how, if at all, their carcinoid
syndrome affected their lives and if certain symptoms
were more impactful than others). Phase II of each
interview focused on carcinoid syndrome symptom
experiences or changes during the clinical trial and the
importance of these changes. Interview participants
were asked to report all improvements (of any
magnitude) noticed during the clinical trial and to
discuss the relative importance of these improvements.
To further quantify the degree of change experienced
(if any) during the clinical trial, 3 questions were
asked during the interviews (Table I). To our
knowledge, these questions had not been used
previously in carcinoid syndrome research. They
were developed with standard Likert scales to
address study objectives.
Interview data were summarized with standard
qualitative analysis methods using field notes and
interview transcripts. RTI Health Solutions developed
a codebook to facilitate the consistent categorization
and organization of carcinoid syndrome symptoms
and effects. Analyses of the quantitative items col-
lected during the exit interviews (questions 1-3) and
selected clinical data (specifically, change in BM
frequency and durable response defined as ≥30%
reduction in BM frequency for ≥50% of the treatment
period) were conducted by the TELESTAR study’s
sponsor and are included in this article.
Clinical Therapeutics
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RESULTS
Participant Demographic Characteristics
A total of 35 patients, of the 135 randomized
cohort patients recruited across 16 clinical sites and 5
countries, completed the exit interview study. Table II
presents the specific demographic characteristics of
patients participating in the interview substudy and
the overall TELESTAR study. All interviews were
conducted between July 2, 2013, and June 15, 2015.
Carcinoid Syndrome Symptom Experiences
Before Study
Interview participants (n ¼ 35) reported experienc-
ing many symptoms related to carcinoid syndrome
before starting the clinical trial. BM-related symptoms
were reported most frequently (ie, too frequent BMs,
diarrhea, loose and watery stools, and urgent BMs).
Table III provides a summary of the carcinoid
syndrome–related symptoms that ≥20% of participants
reported experiencing at baseline.
Too-frequent BMs were the most frequently
reported carcinoid syndrome symptom (34 [97%]).
Selected quotations describing this concept in partic-
ipants’ own words are as follows: “I was up over 10
times a day, which wasn't really acceptable.”; “I did
have days where, you know, 2 minutes after I had left
the bathroom, I'd have to be going back. So those,
probably 15, 20 times a day.”; and “I'd say anywhere
between 5 to 12 as a rule, occasionally more than that.
Occasionally it would get up to maybe 17, 18. But
definitely most days [average] would be 12, 11 to 12.”
Participants commonly described diarrhea as a
multifaceted concept that included 41 BM-related
symptom (most common: loose, watery stools [n ¼ 28];
too frequent BMs [n ¼ 22]; and urgent BMs [n ¼ 16]).
Selected quotations describing these concepts in partic-
ipants’ own words are as follows: “Uncontrollable
diarrhea … It means 5 plus trips to the bathroom …
plus the uncontrollable piece … where you have to go
and there’s no stopping it. You can’t get to a bathroom
fast enough.”; “When all I had to do was try to move
or walk, and I had to go running to the toilet… But by
diarrhea, I mean I'm going to the toilet, you know, 5,
10, 15 times a day.”; and “I mean, I practically had
diarrhea around the clock… It's always runny… the
problem with it is that it's difficult to control because
my entire life or day is scheduled around where the
nearest toilet is.”
Most Important to Treat and Most Bothersome
Carcinoid Syndrome Symptoms
Interview participants’ reports of the 3 most im-
portant symptoms to treat and the 3 most bothersome
symptoms were highly consistent. Diarrhea (n ¼ 17),
BM frequency (n ¼ 9), and urgency (n ¼ 5) were most
frequently identified as the most important carcinoid
syndrome symptom to treat (ie, most frequently
reported as number 1 of the top 3 symptoms to treat).
Table I. Interview questions.
Question 1. Since you started the study medication, would you say that the number of your bowel movements
now is…
1. A great deal better 5. A little worse
2. Much better 6. Much worse
3. A little better 7. A great deal worse
4. The same
Question 2. Since you started the study medication, would you say your stool consistency/form now is…
1. A great deal better 5. A little worse
2. Much better 6. Much worse
3. A little better 7. A great deal worse
4. The same
Question 3. Overall, how satisfied are you with how the study medication relieved your carcinoid syndrome
symptoms?
1. Very satisfied 4. Somewhat dissatisfied
2. Somewhat satisfied 5. Very dissatisfied
3. Neither satisfied nor dissatisfied
L. Anthony et al.
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These 3 symptoms also were ranked as the most
bothersome symptoms by all but 2 interview partic-
ipants. For 29 of the 35 interview participants (83%),
BM frequency was reported as being more important
to treat than stool form or consistency. Twelve of 19
respondents (63%) reported that BM frequency was
the most important aspect of their diarrhea to treat,
followed by urgency in 8 of 19 (42%). None of these
participants reported stool form/consistency as the
most important aspect of their diarrhea to improve.
Effect of Carcinoid Syndrome Symptoms
Negative effects of carcinoid syndrome symptoms
on social and physical activities and hobbies were
reported most frequently, closely followed by emo-
tional and energy areas (Table IV). Interview
participants indicated that certain carcinoid
syndrome symptoms had greater effect on their lives
than others, with too frequent BMs (n ¼ 24) followed
by urgent BMs as the most commonly reported
impactful symptoms (n ¼ 14). Selected quotations
describing these concepts in participants’ own words
elucidate the effect on patients: “Because [frequent
BMs are] the most disruptive. You can't do anything.
You can’t walk around the block. You can't take your
kid to the park. You're homebound.”; Well, because
diarrhea, it’s just so socially absurd. I mean, I couldn't
do anything. I'd be afraid to go out of the house.”;
and When my son got married … he asked me to be
his best man. And I had to turn him down. I told him
that there's a good possibility I might have to leave the
altar if I had to go to the bathroom. I also had to give
up my career, because … you cannot go to the
bathroom when you teach school.”
Treatment Experiences and Changes
Of the 35 interview participants (placebo:250
mg:500 mg ¼ 9:10:16), 34 provided information on
treatment experience. Among them, 24 participants
(placebo:250 mg:500 mg ¼ 4:7:13) reported improve-
ments in their carcinoid syndrome symptoms.
Table II. Participant demographic characteristics.
Characteristic
Interview Substudy
(n ¼ 35)
Overall TELESTAR Study
(n ¼ 135)
Age, mean, y 62 64
Female, % 51 48
White, % 97 90
Baseline body mass index, mean, kg/m2 26 25
Baseline BM frequency, BMs/d 5.76 5.70
Mean BM frequency reduction during 12 weeks, BMs/d –1.11 –1.17
BM ¼ bowel movement.
Table III. Carcinoid syndrome–related symptoms
that ≥20% of interview participants
reported experiencing at baseline.
Symptom
Total No.
(%) (n – 35)
BM-related symptoms
Too frequent BMs 34 (97)
Diarrhea 33 (94)
Loose, unformed, or watery stools 33 (94)
Urgent BMs 30 (86)
Accidents 16 (46)
Abdominal symptoms
Abdominal pain and/or
discomfort
22 (63)
Nausea 14 (40)
Cramping 7 (20)
Other symptoms or effects
Flushing 30 (81)
Low energy 22 (63)
Rapid heart rate, shortness
of breath, or wheezing
7 (20)
BM ¼ bowel movement.
Clinical Therapeutics
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Among these, 21 participants reported their improve-
ments as meaningful or important.
Too frequent BMs was the symptom for which
interview participants most frequently reported improve-
ments (n ¼ 21) (placebo:250 mg:500 mg ¼ 4:7:10), and
20 of 21 participants (95%) who reported reductions in
BM frequency noted that the reduction experienced was
meaningful to them (placebo:250 mg:500 mg ¼ 3:7:10).
When probed as to why this improvement was mean-
ingful, participants consistently reported that their abil-
ity to enjoy life, leave the house, and participate in social
and other activities had been improved by their reduc-
tion in BM frequency. Nearly two-thirds of the patients
who reported an improvement in their BM frequency
indicated that their BMs were “a great deal better” or
“much better.” Selected quotations describing these
concepts, in participants’ own words, are as follows:
“I definitely feel like I'm not a prisoner in my house,
staying 10 feet to the nearest bathroom. I can go out to
activities.” And “But the biggest change is not having to
run to the toilet constantly … You can't live going 20
times a day. I was able to go out more often.”
To further understand the significance of incremental
changes in BM frequency, participants were also asked to
report the smallest reduction in BM frequency that they
would consider meaningful. Patients with more frequent
BMs at baseline generally reported that a greater reduction
in BM frequency would be needed to have a meaningful
change compared with those with less frequent BMs at
baseline (or to move toward normalcy). Because 430%
reduction in BM frequency had been the prespecified
criterion used for the responder analysis in the double-
blind randomized trial, we used the same threshold here to
analyze study participant responses in the exit interviews.
Most participants who provided a response (n ¼ 17/28
[60.7%]) responded with a threshold of ≤30% reduction.
Analyses of Quantitative Interview Items
Among the 33 interview participants (placebo:
250 mg:500 mg ¼ 9:9:15) answering the interview
question about treatment satisfaction (question 3)
(Table I), 58% across all 3 treatment arms reported
being somewhat or very satisfied with the treatment
they received during the TELESTAR study (placebo;
250 mg:500 mg ¼ 3:6:10). Patients with greater
satisfaction reported greater reduction in BM
frequency (Figure 1). The association between
responses to questions was examined using the
Pearson correlation coefficient. A positive correlation
(R ¼ 0.66, P o 0.001) was seen between reported
change in the BM frequency question (question 1)
(Table I) and treatment satisfaction (question 3)
(Table I). In addition, a significant correlation (R ¼
0.54, P o 0.001) was seen between reported change
in the stool form question (question 2) (Table I) and
treatment satisfaction (question 3) (Table I).
All participants who reported satisfaction reported
a reduction in BM frequency, except for one individ-
ual, a participant taking placebo who was only
somewhat satisfied and described minimal changes
until open-label treatment began. None of the 9
patients taking placebo reported being very satisfied
(question 3), whereas 12 of the 24 patients (50%)
taking telotristat ethyl reported being very satisfied
with treatment (Figure 2).
Durable response was a predefined definition of
clinically meaningful change in the TELESTAR study
(at least 30% reduction in BM frequency observed on
at least 50% of days in the study). Among the 9
interview participants with durable responses, one
was taking placebo and was neither satisfied nor
dissatisfied. The other 8 were taking telotristat ethyl,
and all 8 participants (100%) reported being very
satisfied with the ability of study drug to control their
carcinoid syndrome symptoms. All 8 reported mean-
ingful improvement in BM frequency. Only 1 of 8
experienced a BM frequency reduction smaller than
his/her reported threshold for clinically meaningful
change: the patient experienced a 43% reduction
Table IV. Effect of carcinoid syndrome
symptoms reported by ≥20% of
interview participants.
Adverse Effect
Frequency of Reports,
No. (%) (n ¼ 35)
Social and/or physical
activities and hobbies
28 (80)
Emotional 24 (69)
Decreased energy 21 (60)
Occupational (work in
and outside the home)
15 (43)
Travel 15 (43)
Sleep 15 (43)
L. Anthony et al.
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averaged during 12 weeks and described his own
reduction as meaningful and was very satisfied, but
the responses indicated a 55% reduction as a thresh-
old for clinically meaningful change.
Four patients reported being very satisfied without
achieving criteria for durable response. One of them
had no reduction in BM frequency at week 12,
whereas the others were in the range of 10% to
20% reductions. They all described changes in BM
frequency as being small while pointing to related
benefits in gastrointestinal symptoms. All of them
spoke about reductions in urgency and improvements
in stool consistency. Two emphasized strongly an
increase in energy as an important benefit, and one
of them was also encouraged by weight gain as a sign
of improved gastrointestinal function.
Among the interview participants, 8 reported ad-
verse events (placebo:250 mg:500 mg ¼ 2:2:4). These
were communicated to Lexicon Pharmaceuticals, who
ensured that they were all captured in the safety
database. Adverse events on placebo included a report
of increased BM frequency and worsening stool form
and a report of flushing, fatigue, and fogginess.
Both adverse events in the 250-mg group were of
abdominal pain (one accompanied by facial flushing).
Adverse event reports in the 500-mg group were
abdominal pain, constipation with nausea, flushing,
and dizziness with lightheadedness and weight
loss (1 patient each).
DISCUSSION
Patients with carcinoid syndrome have impaired of
quality of life.14 The objective of this exit interview
study was to better understand the experiences of
patients with carcinoid syndrome (eg, symptoms
experienced and effects of those symptoms) and to
obtain insight into the relevance and clinical
meaningfulness of specific symptom improvements and
their associated impact. Elicitation of this information
directly from patients participating in a clinical trial of
telotristat ethyl for the treatment of carcinoid syndrome
yielded a number of important findings.
Participants’ descriptions of the most salient symp-
toms of carcinoid syndrome were highly consistent
and generally focused on BM-related symptoms,
specifically BM frequency. All interview participants
reported experiencing at least too frequent BMs or
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diarrhea at baseline, and only 1 participant did not
initially report too frequent BMs as a symptom.
Patients described diarrhea as a multifaceted symptom
driven not only by stool form and consistency but also
by frequency and urgency. Participants consistently
reported that BM frequency was the most important
and most bothersome aspect of their diarrhea to treat,
and most participants (83%) reported that an im-
provement in BM frequency was more important than
an improvement in stool form or consistency.
Participants also described the effect their carcinoid
syndrome symptoms had on their lives as significant.
This effect included emotional effects (anxiety about
leaving their homes and potentially not finding a
bathroom), the inability to engage in social activities
(social activities and hobbies) and physical activities
(such as exercise), and difficulty retaining employment
(occupational and financial). When asked what symp-
toms had the greatest effect, participants reported too
frequent BMs more often than any other symptom.
Most interview participants across treatment
groups (62%) reported a reduction in their BM
frequency by the end of the clinical trial, and all but
1 of these participants noted that this improvement
was meaningful. Participants who experienced a
meaningful reduction in BM frequency reported im-
provements in emotional well-being and social and
physical functioning. Furthermore, 81% of partici-
pants who reported an improvement in BM frequency
reported being either somewhat satisfied or very
satisfied with the study medication. The highest level
of treatment satisfaction was reported only with
telotristat ethyl not placebo.
Taken together, these findings indicate the substantial
burden patients with carcinoid syndrome experience and
that too frequent BMs play an integral role in this
burden. The interview data clearly support the impor-
tance of the TELESTAR study’s primary end point:
change in BM frequency. The interview results also
support the relevance of the prespecified responder
analysis (≥30% reduction in BM frequency) because
all patients taking telotristat ethyl who met responder
criteria were very satisfied with treatment. These results
assist in the interpretation of the clinical trial data and
further support the clinical meaningfulness of the symp-
tom changes reported in the TELESTAR study.
This understanding is important because numeric
changes in BM frequency can be difficult to interpret.
Some experts have been cautious in describing the
meaning and magnitude of clinical trial results.19 This
interview study may provide a useful guide. It suggests
that BM frequency reductions in TELESTAR were
sufficient to have a substantial effect on the lives of
patients with carcinoid syndrome.
Poor stool consistency was a problem for many
patients, but improving stool consistency was not as
important as reducing BM frequency. Interview tran-
scripts did not directly link stool consistency to
physical or social function. When some patients
communicated a desire for better stool consistency,
they described it as a sign of better gastrointestinal
function. In contrast, the large number of BMs was
directly limiting the lives of patients.
During TELESTAR, the QLQ-C30 and European
Organisation for Research and Treatment of Cancer
Gastrointestinal Neuroendocrine Tumours question-
naires20 were applied to all patients. These questionnaires
provided a systematic assessment supported by prior
scientific literature, complementing the exit interview data
that connected patient symptoms and experiences. In the
QLQ-C30, diarrhea subscale arithmetic mean scores
averaged during the 12-week study period improved by
19.2 and 21.6 points (on a rating scale of 0 to 100) in the
telotristat ethyl 250 mg TID and 500 mg TID groups,
respectively, and by only 8.5 in the placebo group
(P ¼ 0.039 for telotristat ethyl 250 mg and P ¼ 0.051
for telotristat ethyl 500 mg compared with placebo).
Changes greater than 10 are considered clinically
meaningful.21 These results are consistent with those of
the exit interview study.
The design of this qualitative exit interview study
has several advantages and limitations. When con-
ducted with scientific rigor and expertise, qualitative
research of this type has the potential to further
explain clinical trial findings, ensure interventions
meet the needs of health care professionals and
patients, and ensure that the right instruments are
used to measure the outcomes of interest.22 In this
case, the feedback of interview participants
characterizes the effect of the symptoms of carcinoid
syndrome on patients’ lives and emphasizes the
importance of a reduction in BM frequency, thus
supporting the primary end point and responder
analysis of the TELESTAR study.
The decision to perform the interviews as a sub-
study related to logistics and sample size considera-
tions. Logistically, there was concern that an effort to
include many more patients would require more
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personnel and translations, potentially introducing
inconsistencies in the data. A prior study in the area
of rheumatoid arthritis with disease flares had sug-
gested that 20 interviews were sufficient to provide
reliable and valid interpretations of subjective well-
being.23 Therefore, we believed that the sample of 35
patients would likely provide a reasonable assessment
of how carcinoid syndrome affected patients’ lives.
There was no formal validation exercise conducted
as part of this study. Such an exercise would be
standard in the development of an itemized question-
naire intended for systematic, quantitative assessments
and repeated use in different settings. Instead, this
study was intended to broadly describe and identify
patient perspectives in TELESTAR. The close relation-
ships between observed BM frequency change in
TELESTAR and interview responses suggest that
relevant perspectives were identified.
That said, caution should be used in interpreting
findings from this study. Although all participants easily
described their experiences with carcinoid syndrome
before and during the TELESTAR trial, a limitation of
this study is the recall bias involved in thinking back
over a 12-week treatment period. In addition, the
sample size was limited, so the results should be treated
as a description of the trial experience rather than as an
exercise in testing specific hypotheses for statistical
significance. A common concern is that patients who
choose to participate in interviews are those who
experience a more favorable outcome, but participants
in this study were invited and scheduled to participate in
interviews before randomization. Their reductions in
BM frequency were not any greater than that of the
overall TELESTAR study.
It is also important to compare the characteristics
of this subset of patients to those overall in the
TELESTAR study. The demographic characteristics
and even BM frequency reductions seen in the inter-
view data were similar to those of the TELESTAR
study overall, yet it would be ideal in future exercises
to include all clinical study patients if feasible.
CONCLUSION
The results of this exit interview indicate that frequent
and urgent BMs were the most important symptoms
to treat. Participants reported that improvements in
these symptoms allowed them to better enjoy life,
leave the house, and participate in social and other
activities. These patient perspectives support the
significance of the primary end point and clinical
responder analysis in the TELESTAR study, helping
identify and understand clinically meaningful changes
produced by telotristat ethyl.
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